相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier et al.
BLOOD (2021)
PRELIMINARY BIOMARKER AND CLINICAL ATA OF A PHASE 2A STUDY OF NT-I7, A LONG-ACTING INTERLEUKIN-7, PLUS PEMBROLIZUMAB: COHORT OF SUBJECTS WITH CHECKPOINT INHIBITOR-NAIVE ADVANCED PANCREATIC CANCER
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
INITIAL BIOMARKER AND CLINICAL DATA OF A PHASE 2A STUDY OF NT-I7, A LONG-ACTING INTERLEUKIN-7, PLUS PEMBROLIZUMAB: COHORT OF SUBJECTS WITH CHECKPOINT INHIBITOR-NAIVE ADVANCED MSS-COLORECTAL CANCER
Richard Kim et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence
Scott M. Krummey et al.
CELL REPORTS (2020)
hhIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects
Sang Won Lee et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq
Angela C. Boroughs et al.
MOLECULAR THERAPY (2020)
Single-cell landscape of immunological responses in patients with COVID-19
Ji-Yuan Zhang et al.
NATURE IMMUNOLOGY (2020)
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
Hong Luo et al.
CLINICAL CANCER RESEARCH (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Two subsets of stem-like CD8+memory T cell progenitors with distinct fate commitments in humans
Giovanni Galletti et al.
NATURE IMMUNOLOGY (2020)
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
John Rossi et al.
BLOOD (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial
Bruno Francois et al.
JCI INSIGHT (2018)
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Somala Mohammed et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Biophysical stability of hyFc fusion protein with regards to buffers and various excipients
Jun Yeul Lim et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients
O. Tredan et al.
ANNALS OF ONCOLOGY (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Ayal Hendel et al.
NATURE BIOTECHNOLOGY (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
PLOS ONE (2013)
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
Miguel-Angel Perales et al.
BLOOD (2012)
Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
Claude Sportes et al.
CLINICAL CANCER RESEARCH (2010)
Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant
Hyo Jung Nam et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
Claude Sportes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression
P Westervelt et al.
BLOOD (2003)
分享论文
